📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! Tell us what works, what doesn't, and how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community. Please send your feedback to gateway@ukri.org by 11 August 2025.

Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. (2021)

First Author: Kennedy NA

Attributed to: Regulatory T cell therapy for IBD funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/gutjnl-2021-324789

PubMed Identifier: 33903149

Publication URI: http://europepmc.org/abstract/MED/33903149

Type: Journal Article/Review

Volume: 70

Parent Publication: Gut

Issue: 10

ISSN: 0017-5749